Thermo Fisher Enters into Definitive Agreement to Acquire Solventum’s Purification and Filtration Business

Thermo Fisher Enters into Definitive Agreement to Acquire Solventum’s Purification and Filtration Business

Client News

Related Solutions

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
WilmerHale lawyers have decades of experience advising public and private companies in all aspects of mergers and acquisitions.

On February 25, 2025, Thermo Fisher Scientific Inc., the world leader in serving science, announced its definitive agreement to acquire Solventum’s purification and filtration business for approximately $4.1 billion. Solventum’s innovative filtration portfolio broadens Thermo Fisher’s capabilities in the development and manufacturing of biologics, spanning upstream and downstream workflows. The transaction is expected to be completed by the end of 2025 and is subject to customary closing conditions and regulatory approvals. Once the transaction closes, Solventum’s purification and filtration business will become part of Thermo Fisher's Life Sciences Solutions segment.

The WilmerHale team representing Thermo Fisher was led by Hal Leibowitz and Andrew Bonnes and included, Andy Alin, Joseph Minko, Rebecca Nauta, Will Myer, Sarah Matchett, Taylor Mielnicki, Molly Nelson, Ashton Kennedy, Arpi Youssoufian, Joseph Odegaard, Noah Levin, Stephen Gillespie, Aron Nimani, Bill Caporizzo, Meghan Walsh, Benjamin Kelsey, Douglas Burton, Michael Kaplan, Brett Jackson, Benjamin Unger, Armen Grigorian, Kirk Nahra, Ali Jessani, Scott Kilgore, Amanda Albert, Barry Hurewitz, Leslie Harrelson, Jarrod Carman, Bruce Manheim, David Gold, Katie Raitz and Alex Daniel.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel